SEC Form 4 · accession 0001209191-18-062117
Tempest Therapeutics, Inc. · TPST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James M. Hindman
Director
Period of report
Dec 7, 2018
Accepted (ET)
Dec 11, 2018 · 7:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001544227
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $6.59 | Dec 7, 2018 | A | 17,509 | A | — | Aug 9, 2026 | Common Stock | 17,509 | 17,509 | D |
| Stock Option (right to buy)F4,F3 | $16.40 | Dec 7, 2018 | A | 3,720 | A | — | Aug 23, 2028 | Common Stock | 3,720 | 3,720 | D |
Explanation of responses
- F1Twenty-five percent (25%) of the shares subject to the option vested on June 17, 2017, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
- F2Received in connection with the merger of Millendo Therapeutics, Inc. ("Millendo") into the Issuer (the "Merger") in exchange for a stock option to acquire 235,341 shares of Millendo common stock for $0.49 per share.
- F3Twenty-five percent (25%) of the shares subject to the option shall vest on August 20, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
- F4Received in connection with the Merger in exchange for a stock option to acquire 50,000 shares of Millendo common stock for $1.22 per share.